Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence

Alicia S. Ventura, MPH\(^{a,b,*}\), Michael R. Winter, MPH\(^{a}\), Timothy C. Heeren, PhD\(^{d}\), Meg M. Sullivan, MD\(^{b}\), Alexander Y. Walley, MD, MSC\(^{c}\), Michael F. Holick, PhD, MD\(^{d}\), Gregory J. Pattis, MPH\(^{c}\), Seville M. Meli, MPH\(^{b}\), Jeffrey H. Samet, MD, MA, MPH\(^{a,b}\), Richard Saitz, MD, MPH\(^{a,b}\)

**Abstract**

Low bone mineral density (BMD) is common in people living with HIV infection (PLWH), increasing fracture risk. Alcohol use is also common in PLWH and is a modifiable risk factor for both HIV disease progression and low BMD. In PLWH, alcohol’s effect on BMD is not well understood.

We studied adult PLWH with substance dependence. We measured lifetime alcohol use (kg) and recent (i.e., past 30-day) alcohol use (categorized as: abstinent, low risk, or high risk). In adjusted multivariable regression analyses, we tested associations between lifetime and recent alcohol use and (i) mean BMD (g/cm\(^2\)) at the femoral neck, total hip, and lumbar spine and (ii) low BMD diagnosis (i.e., osteopenia or osteoporosis). We also examined associations between 2 measures of past alcohol use (i.e., total consumption [kg] and drinking intensity [kg/year]) and BMD outcome measures during 3 periods of the HIV care continuum: (i) period before first positive HIV test, (ii) period from first positive HIV test to antiretroviral therapy (ART) initiation, and (iii) period following ART initiation.

We found no significant associations between lifetime alcohol use and mean femoral neck (\(B = -0.000, P = .62\)), total hip (\(B = -0.000, P = .83\)) or lumbar spine (\(B = 0.001, P = .65\)) BMD (g/cm\(^2\)), or low BMD diagnosis (adjusted odds ratio [aOR] = 0.98, 95% Confidence Interval [CI]: 0.95–1.01). There was no significant correlation between past 30-day alcohol use and mean BMD (g/cm\(^2\)). Past 30-day alcohol use was associated with low BMD diagnosis (\(P = .04\); compared to abstainers, the aOR for high risk alcohol use was 1.94 (95% CI: 0.91–4.12), the aOR for low risk alcohol use was 4.32 (95% CI: 1.30–14.33). Drinking intensity (kg/year) between first positive HIV test and ART initiation was associated with lower mean BMD (g/cm\(^2\)) at the femoral neck (\(B = -0.006, P = .04\)) and total hip (\(B = -0.007, P = .02\)) and increased odds of low BMD (aOR = 1.18, 95% CI = 1.03–1.36).

In this sample of PLWH, we detected no association between lifetime alcohol use and BMD. However, recent drinking was associated with low BMD diagnosis, as was drinking intensity between first positive HIV test and ART initiation. Longitudinal studies should confirm these associations.

**Abbreviations:** 25(OH)D = 25-hydroxy-vitamin D, aOR = adjusted odds ratio, ART = antiretroviral therapy, BMD = bone mineral density, BMI = body mass index, CI = confidence interval, DSM-IV = Diagnostic and Statistical Manual of Mental Disorders 4th edition, DXA = dual energy x-ray absorptiometry, FN = femoral neck, GE = General Electric, LS = lumbar spine, NHANES III = Third National Health and Nutrition Examination Survey, PLWH = people living with HIV, SD = standard deviation, TH = total hip, TLFB = Timeline Followback, US = United States, WHO = World Health Organization.

**Keywords:** alcohol, bone density, HIV, lifetime drinking, treatment cascade
1. Introduction

Low bone mineral density (BMD) is common in people living with HIV infection (PLWH); osteoporosis is 3 times more common in PLWH than in uninfected populations.[1] Low BMD is a risk factor for fracture in PLWH.[2] Fractures are more common among PLWH than among uninfected controls[3–6] and the general, age-matched US population.[7,8] Fracture, a serious cause of morbidity and mortality, is expected to become a significant cause of impairment in aging PLWH. The etiology of low BMD in PLWH is multifactorial, ranging from HIV infection itself, to treatments for HIV infection, to co-existing risks and exposures.[9]

In the absence of antiretroviral therapy (ART), HIV infection is independently associated with a loss of BMD likely due to immune activation, viral, and inflammatory effects that disrupt bone remodeling.[10–13] In vitro and in vivo studies have demonstrated the direct effects of HIV on bone formation by suppressing osteoblast activity,[14] and on bone resorption by stimulating osteoclast activity,[15] resulting in an uncoupling and subsequent loss of bone mass.

In individuals taking ART, BMD decreases by an estimated 2%–6% within the first 2 years following initiation, regardless of medication regimen.[16–24] Specific ART regimens (i.e., tenofovir,[25] and to a lesser degree, protease inhibitors[26]) have been associated with accelerated decline in BMD. Immune reconstitution, or the repopulation of T-cells, which immediately follows initiation of ART, can prompt production of inflammatory cytokines and may partly explain the mechanism of BMD decline common to all ART regimens.[27,28]

Traditional risk factors and secondary causes for low BMD and osteoporosis (e.g., low body mass index, weight loss, smoking, hepatitis C coinfection, secondary hyperparathyroidism, and chronic kidney disease) are highly prevalent and strongly associated with low BMD in PLWH.[29,30] Other risk factors for decreased BMD prevalent in PLWH include: vitamin D deficiency,[31,32] physical inactivity,[33] alcohol use,[34] opioid use,[35,36] and cocaine use.[36]

Alcohol use, commonly identified as a risk factor for low BMD in the general population, is prevalent in PLWH.[37–42] Alcohol has a toxic effect on bone, due to decreased bone formation,[43–47] likely exacerbated by hormonal, inflammatory, and dietary factors associated with alcohol use.[48] "Moderate" alcohol consumption has been associated with increased BMD,[49–51] though a 2008 review concluded that the variability in measures used to assess alcohol use across studies made it impossible to determine the presence or magnitude of a dose–response relationship.[52] Studies of alcohol and BMD have used little or no detailed validated measurement of recent or lifetime alcohol use; effects of prolonged alcohol exposure on BMD remain largely unknown.

The population of PLWH is aging and many individuals have been exposed to multiple risk factors for low BMD—such as alcohol and ART—for decades. Lifetime drinking trajectories of PLWH are heterogeneous and alcohol use changes following entry into the HIV care continuum (i.e., HIV diagnosis).[53] Yet the cumulative effects of recent and lifelong exposure to alcohol on BMD in PLWH are unknown. Further, BMD may be more susceptible to the effects of alcohol in PLWH during certain periods due to factors previously described, representing potential targets for interventions. Accordingly, this study assessed the association between total lifetime and recent alcohol consumption and BMD. Additionally, we conducted an exploratory analysis to examine associations between past alcohol use during 3 periods of the HIV care continuum and BMD (Fig. 1): (i) period prior to first positive HIV test, (ii) period from first positive HIV test to ART initiation, and (iii) period following initiation of ART.

2. Methods

2.1. Participants

Research participants were in the Boston ARCH Cohort, a study to examine the effect of alcohol on bone health in PLWH with substance dependence. Participants were recruited between December 2012 and November 2014 from an urban academic hospital-based HIV primary care clinic and a community health center-based HIV primary care clinic serving homeless men and women. Inclusion criteria were: (1) documentation of HIV infection in any medical record, determined by confirmatory HIV testing algorithm approved by the Massachusetts Department of Public Health at time of screening, or HIV viral load ≥10,000 copies/mL; (2) past 12-month Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) drug or alcohol dependence assessed by Mini International Neuropsychiatric Interview (M.I.N.I. 6.0) or ever injection drug use; (3) ability to speak English; (4) ≥18 years old; (5) willingness to provide contact information ≥1 person. Exclusion criteria were: (1) pregnancy (assessed by urine test); (2) plans to leave the Boston area in the next year; (3) cognitive impairment resulting in inability to provide informed consent. Additional inclusion criteria specific to the current study included: (1) completion of the Lifetime Drinking History and (2) BMD measured at ≥1 bone sites at study entry.

Participants provided written informed consent and received compensation for completing study assessments. The Boston University Medical Campus Institutional Review Board approved the study, including follow-up of incarcerated participants, and we obtained a Certificate of Confidentiality from the National Institute on Alcohol Abuse and Alcoholism.

2.2. Primary outcome variables

The primary outcome variables were BMD measured by dual energy x-ray absorptiometry (DXA) in grams per square centimeter (g/cm²) at the femoral neck (FN), total hip (TH), and lumbar spine (LS) (L₁–L₄). All measurements were performed by bone densitometry technologists certified by the International Society for Clinical Densitometry. Due to machine availability, baseline measurements were completed on 3 densitometers: (1) Hologic QDR 4500 Discovery W (software version 12.6.1) (Waltham, MA); (2) Hologic QDR 4500 Discovery W (software version 13.4.2) (Waltham, MA) (a replacement for the first densitometer); and (3) General Electric (GE) Lunar iDXA (GE Healthcare, Madison, WI). The 2 Hologic DXAs were cross-calibrated using a standard phantom. All BMD measurements taken from the GE Lunar iDXA were converted to Hologic-equivalent values by applying industry-accepted conversion formulas.[54]

2.3. Secondary outcome variable

The secondary outcome variable was low BMD diagnosis (dichotomous) defined by T-score indicative of osteopenia or osteoporosis at ≥1 bone site (i.e., TH, FN, or LS) versus normal
BMD at all sites. T-scores, expressed in standard deviations (SDs), compare the site-specific BMD value with the mean peak BMD value of a young healthy reference population of the same sex and race/ethnicity. FN and TH T-scores were calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference database; LS T-scores were calculated from the manufacturer-supplied U.S. Hologic QDR reference database. Consistent with World Health Organization (WHO) Guidelines, normal BMD was defined as a T-score between 1 and −1.45 Osteopenia was defined as a T-score < −1.0 and ≥ −2.5 and osteoporosis was defined as a T-score < −2.5.

2.4. Main independent variable

The main independent variable was total lifetime alcohol use summarized in 100 kilogram (kg) units, assessed by the Lifetime Drinking History and administered as a supplement to the first follow-up assessment after study entry (for most, within 6 months). The Lifetime Drinking History is a structured interview that provides detailed data on patterns of alcohol use throughout an individual’s lifetime. Chronologically, the interviewer collected information beginning with onset of regular drinking (i.e., ≥ 1 drink per month) about quantity, frequency and variability of alcohol consumption, and life events that marked a change in alcohol use—recording each phase of alcohol use (or abstinence) in the participant’s lifetime. The reliability and validity of the Lifetime Drinking History has been well established. Further, lifetime alcohol exposure derived from the Lifetime Drinking History has been found to be associated with adverse health outcomes, such as alcoholic liver disease, which may not be easily predicted by episodic risky drinking.

2.5. Additional independent variables: recent and past alcohol use

In face-to-face interviews at study entry, we assessed past 30-day drinking by Timeline Followback (TLFB, a validated calendar method for measuring past month daily alcohol use). The past 30-day alcohol use was categorized into 3 groups using a standard high risk threshold associated with alcohol use disorder, injury, or other alcohol-related health problems: (i) no alcohol, (ii) low risk use, or (iii) high risk use. High risk alcohol use was defined as ≥14 standard drinks (standard drink = 14 g ethanol) per week on average for males (>7 for females) or ≥1 heavy drinking day (>4 drinks in a day for males, >3 for females).

From the Lifetime Drinking History, we calculated: (1) total alcohol consumption (kgs) and (2) drinking intensity (10 kg/year) for each of the 3 periods displayed in Fig. 1. When age of first positive HIV test or initiation of ART fell in the middle of a phase on the Lifetime Drinking History, total alcohol consumption for the phase was applied proportionally to each period. If a participant reported that first positive HIV test and initiation of ART occurred in the same year, both total alcohol consumption and drinking intensity for Period 2 were coded as “0.”

2.6. Covariates

We assessed the following by in-person interview at study entry: age, biological sex, race/ethnicity, smoking, weight-bearing physical activity, lowered sexual drive, menopausal status, and average daily calcium intake (mg). Years of regular cocaine and heroin use were assessed using the Addiction Severity Index. We also assessed ever exposure to illicit or prescribed opioids, ever exposure to tenofovir, and duration of HIV infection.

At study entry, each participant’s medical record was reviewed and the most recent CD4 cell count (cells/mm^3) and HIV viral load (copies/mL) values were recorded. If not available within 3 months of study entry, we tested them. Blood was tested for total 25-hydroxy-vitamin D (25(OH)D) by liquid chromatography-tandem mass spectrometry. Height and weight were used to calculate body mass index (BMI). DXA manufacturer, and software version were also included as covariates.

2.7. Statistical analysis

All analyses were conducted using SAS software, Version 9.3 (SAS Institute Inc., Cary, NC). Influential outliers were identified using Cook’s Distance and Studentized Residuals. Covariates were chosen for inclusion in models based on factors known to affect BMD. We checked for possible co-linearity of all independent variables and covariates. For pairs of variables with a Spearman’s rho >0.43 or < −0.43, only 1 variable was included in each regression model. Years of HIV infection and years of ART were highly correlated (r=0.69), as were years of regular heroin use and ever injection drug use (r=0.66); years of HIV infection and years of regular heroin use were selected for inclusion in regression models. Adjusted odds ratios (aOR), mean adjusted changes (betas, as appropriate) and 95% confidence intervals (CI) are reported for each model. All analyses were conducted using 2-sided tests and a significance level of 0.05.

Primary analyses evaluated the associations between total lifetime alcohol use, recent alcohol use, and each outcome variable: FN, TH, and LS BMD (g/cm^2), and low BMD diagnosis. Separate adjusted multivariable regression models were fit to evaluate the association between total lifetime alcohol use (100 kg units) and each outcome variable, adjusting for all aforementioned covariates. Models were repeated using FN, TH, and LS T-scores as outcome variables (see Supplementary Content Table 6, http://
links.lww.com/MD/B676 for results of regression models). Due to use of multiple DXA machines, we performed a sensitivity analysis; each regression model was stratified by type of DXA machine and software version used. Results of the sensitivity analyses were similar to those of the primary analyses and are not shown.

Exploratory models were fit to assess whether total alcohol consumption (kg) during 3 periods of the HIV care continuum (Fig. 1) was associated with TH, FN, and LS BMD (g/cm²), and low BMD diagnosis. To assess for an independent association with each time period, multivariable regression models were fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same model. A second set of multivariable regression models were fit to assess associations between drinking intensity (10 kg/year) during Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same model. A second set of multivariable regression models were fit to assess associations between drinking intensity (10 kg/year) during Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same model. A second set of multivariable regression models were fit to assess associations between drinking intensity (10 kg/year) during Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same model. A second set of multivariable regression models were fit to assess associations between drinking intensity (10 kg/year) during Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same multivariable regression models, total lifetime alcohol consumption (kg) was not fit to include Period 1, 2, and 3, recent alcohol consumption, and all covariates, in the same...
diagnosis (i.e., osteopenia or osteoporosis defined by T-score) (Table 4).

3.2.2. Recent alcohol use. Compared with those reporting no alcohol use in the past 30 days, participants reporting high risk drinking (aOR = 1.94, 95% CI: 0.91–4.12) and low risk drinking (aOR = 4.32, 95% CI: 1.30–14.33) had greater odds of low BMD diagnosis. The past 30-day use was not significantly associated with FN, TH or LS BMD (g/cm²). (See Supplementary Content Table 7, http://links.lww.com/MD/B676 for full results of multivariable regression models, including all covariates.)

3.3. Multivariable models of drinking intensity across the HIV care continuum and BMD

3.3.1. Lifetime alcohol use. In adjusted multivariable regression models that included drinking intensity (increments of 10kg/year) for Periods 1, 2, and 3 in the same model, drinking intensity during Period 1 (i.e., initiation of drinking to first positive HIV test) was associated with decreased odds of low BMD diagnosis and was not associated with FN, TH, or LS BMD (g/cm²) (Table 5). Drinking intensity during Period 2 (i.e., first positive HIV test to initiation of ART) was associated with higher odds of low BMD diagnosis and lower FN, TH, and LS BMD (g/cm²). Drinking intensity during Period 3 (i.e., initiation of ART to time of assessment) was associated with lower odds of low BMD diagnosis and higher FN, TH, and LS BMD (g/cm²).

3.3.2. Recent alcohol use. Compared with participants reporting no alcohol use in the past 30 days, participants who reported high risk drinking (aOR = 2.22, 95% CI: 1.01–4.88) and low risk drinking (aOR = 4.34, 95% CI: 1.26–14.91) had greater odds of low BMD diagnosis. (See Supplementary Content Table 8, http://links.lww.com/MD/B676 for full results of multivariable regression models, including total alcohol consumption [kgs] for each period of the HIV care continuum and all covariates. See Supplementary Content Table 9, http://links.lww.com/MD/B676 for full results of multivariable regression models, including alcohol intensity [10kg/year] for each period of the HIV care continuum and all covariates.)

4. Discussion

The main objective of this study was to assess the association between alcohol use—particularly lifetime use—and BMD in
Table 4

Adjusted multivariable regression models assessing associations between total lifetime alcohol use (100kg) and femoral neck, total hip, and lumbar spine bone mineral density (g/cm²) and low bone density∗∗∗.

| Variable                        | Femoral neck BMD, g/cm² n = 235 | Total hip BMD, g/cm² n = 235 | Lumbar Spine BMD (g/cm²) n = 236 | Low bone density n = 237 |
|---------------------------------|---------------------------------|-------------------------------|---------------------------------|-------------------------|
|                                  | Adjusted beta (95% CI)          | Adjusted beta (95% CI)        | Adjusted Beta (95% CI)          | aOR (95% CI)            |
| Total lifetime alcohol use (100kg) | −0.000 (−0.002–0.001)          | −0.000 (−0.002–0.002)        | 0.001 (−0.002–0.003)           | 0.98 (0.95–1.01)        | 0.16 |
| Past 30-day risky alcohol use Abstinent [ref] | 0.73                            | −0.010 (−0.062–0.043)        | −0.015 (−0.078–0.048)           | 4.32 (1.30–14.33)       | 0.04 |
| Low risk use | −0.019 (−0.071–0.034)          | −0.011 (−0.050–0.029)        | −0.030 (−0.077–0.017)           | 1.94 (0.91–4.12)        |      |
| High risk use | −0.012 (−0.052–0.027)          | −0.011 (−0.050–0.029)        | −0.030 (−0.077–0.017)           | 1.94 (0.91–4.12)        |      |

aOR—adjusted odds ratio; BMD—bone mineral density; CI—confidence interval; ref—reference group.

*p Covariates included in all models: included: age, sex, race, BMI, current smoking status, menopause, ever opioid exposure, CD4 cell count, HIV viral load ≥ 250 copies/mL, total CD4, ever tenofovir use, daily calcium intake, past-year loss of sex drive, years of HIV infection, weight-bearing physical activity, years of regular cocaine use, years of regular heroin use, DXA machine/software version (see Supplemental Content Table 7, http://links.lww.com/MD/B676).

**Lifetime alcohol consumption was not associated with baseline FN, TH or LS T-score; statistical significance and direction of associations between all covariates and each T-score were similar to associations with BMD, with the exception of sex which was significantly associated with FN T-score (Adjusted b=0.50 SDs; P = .01) (see Supplemental Content Table 6, http://links.lww.com/MD/B676).

***1 Participant with extreme FN BMD value and extreme total lifetime alcohol consumption was excluded from all regression models for which FN or TH BMD were the primary outcome. Another participant with an extreme LS value was excluded from all regression models for which LS BMD was the primary outcome. 1 participant was unable to contribute BMD measurements for any site due to a positioning error that occurred during both DXA scans.
We expected to find that alcohol use would be associated with BMD. We expected long-term exposure to be important for BMD, and shorter term exposure to have little effect. We expected that alcohol would have different effects based on its use before and after HIV diagnosis and ART initiation. Overall we found little effect of alcohol on BMD except a possible detrimental effect of recent use, and possible effects of use between HIV testing and ART initiation. These findings should be placed in the context of prior literature.

Tianji et al found markers of bone resorption were elevated and not matched by increases in bone formation in PLWH, and that the latter were significantly associated with any past 30-day alcohol use. Animal studies have demonstrated that alcohol consumption suppresses bone formation with no effect or an increased effect on bone resorption. High rates of alcohol consumption have been associated with increased risk of fracture in PLWH; the role of BMD is not clear and could be related to injury risk. In a large 10-year cohort study of PLWH, the incidence of fracture was 2.9 times greater among those reporting heavy drinking. Yet, studies have not consistently identified an association between alcohol consumption and BMD in people with and without HIV infection, and without alcohol use. Possibly because most studies do not include measures of lifetime alcohol use, and many do not include valid detailed measures of recent use.

BMD does decline following initiation of ART and it occurs rapidly; increased markers of bone resorption have been detected as early as 2 weeks after initiation of ART. Longitudinal studies have found that this BMD decrease post-ART is not permanent, and that BMD stabilizes or increases after about a year of ART. In studies of HIV-uninfected adults, the deleterious effects of alcohol on bone also occur rapidly; it is unclear if the alcohol-induced changes to bone metabolism are permanent. In PLWH, any possible differential effects of alcohol on bone pre- and post-ART are not well understood.

Our findings should be considered in the context of study limitations. Although the Lifetime Drinking History is a validated instrument, it relies on self-report and may be subject to recall and social desirability bias. The dates assigned to events (e.g., ART initiation) may also be subject to recall bias, which could result in imprecise measures of alcohol use across the HIV care continuum. We do not, however, have reason to believe that there are biases that would affect the association between alcohol use and BMD. Quantity measures (e.g., lifetime alcohol consumption) do not account for drinking patterns and therefore we cannot discern differences between individuals who may have consumed large quantities of alcohol in a short time period from those who consumed the same amount over a longer time period. However, in this cohort, total lifetime alcohol consumption and years of very heavy drinking were highly correlated, making the distinction between total consumption and drinking pattern less relevant.

Study participants had current substance dependence or ever injection drug use at time of enrolment; therefore, our findings may not be generalizable to other PLWH. In fact, the real-world context of multiple competing risks in our cohort may partially explain our findings. We used 3 different DXA machines to measure BMD, which could introduce measurement error as measurements can vary between manufacturers by as much as 11%. We did however use an industry-accepted conversion formula to account for between-machine differences, performed a sensitivity analysis stratifying results by DXA machine, and controlled for DXA machine and software version in all regression models.

The study has a number of strengths. We enrolled a sample of PLWH at high risk for low BMD, and assessed alcohol use using validated tools, identified numerous potential confounders, and measured BMD in a standardized fashion. To evaluate cumulative effects, we obtained detailed information on past and recent alcohol use from 98% of participants, most reporting decades of alcohol exposure. We examined associations in a number of different ways to look for consistent findings. Although the sample size was modest, the primary null findings for the association between lifetime alcohol use and bone density are robust with effect sizes of 0 and confidence intervals of ~0.004 g/cm², consistent across several analyses.

In conclusion, we did not detect an association between lifetime alcohol consumption and bone mineral density (BMD). We did

### Table 5

| Independent variable | Femoral neck BMD, g/cm², n = 235 | Total hip BMD, g/cm², n = 235 | Total spine BMD, g/cm², n = 236 | Low bone density, n = 237 |
|----------------------|---------------------------------|--------------------------------|---------------------------------|--------------------------|
|                      | Adjusted beta (95% CI) | P value | Adjusted beta (95% CI) | P value | Adjusted beta (95% CI) | P value | aOR (95% CI) | P value |
| Period 1 drinking intensity, 10 kg/year | 0.004 (−0.003–0.011) | 0.29 | 0.004 (−0.003–0.011) | 0.27 | 0.002 (−0.006–0.009) | 0.67 | 0.87 (0.76–0.99) | 0.04 |
| Period 2 drinking intensity, 10 kg/year | 0.006 (−0.012–0.001) | 0.02 | −0.007 (−0.012–0.001) | 0.02 | 0.006 (−0.013–0.000) | 0.05 | 1.18 (1.03–1.36) | 0.02 |
| Period 3 drinking intensity, 10 kg/year | 0.005 (0.003–0.010) | 0.04 | 0.006 (0.001–0.011) | 0.02 | 0.009 (0.001–0.013) | 0.02 | 0.85 (0.75–0.96) | 0.01 |
| Past 30-day risky alcohol use* | 0.016 (−0.055–0.023) | 0.71 | 0.014 (−0.053–0.025) | 0.74 | 0.012 (−0.074–0.050) | 0.39 | 0.03 |
| Low risk use | −0.012 (−0.064–0.040) | 0.02 | −0.002 (−0.054–0.050) | 0.02 | −0.012 (−0.074–0.050) | 0.02 | 4.34 (1.26–14.91) | 0.02 |
| High risk use | −0.016 (−0.055–0.023) | 0.02 | −0.014 (−0.053–0.025) | 0.02 | −0.032 (−0.079–0.015) | 0.02 | 2.22 (1.01–4.88) | 0.05 |

aOR = adjusted odds ratio, BMD = bone mineral density, CI = confidence interval, ref = reference group.

Covariates included in all models: age, sex, race, BMI, current smoking status, menopause, ever opioid exposure, CD4 cell count, HIV viral load ≥200 copies/mL, total 25(OH)D, ever tenofovir use, daily calcium intake, past-year loss of sex drive, years of HIV infection, weight-bearing physical activity, years of regular cocaine use, years of regular heroin use, DXA machine/software version (see Supplemental Content Table 9, http://links.lww.com/MD/B676). Again, compared with participants reporting no alcohol use in the past 30 days at baseline, participants whose alcohol use exceeded the risky drinking threshold (AOR = 4.32, 95% CI: 1.30–14.33) and those who reported alcohol use but did not exceed the risky drinking threshold (AOR = 1.94, 95% CI: 0.91–4.12) had greater odds of low baseline BMD. No significant association was detected between FN, TH, or LS BMD (g/cm²) and past 30-day alcohol use in this set of models.
Acknowledgments

The authors dedicate this publication to the memory of their colleague Adrian K. Turner, who was instrumental in collection and interpretation of bone scan data, and died before data collection was completed. We would like to thank the Boston ARCH Cohort study participants for the time and effort they have dedicated to this research. We also wish to thank all staff at Boston University and Boston Medical Center who supported this project. Specifically, we want to acknowledge Margo Godersky, Kate Haworth, Keshia Toussaint, and Laura Vercammen for their work in recruitment, data collection, and participant retention; and Katherine Calver for her thoughtful review of this manuscript. Lastly, we also wish to acknowledge the staff of the General Clinical Research Unit at Boston University, Center for Infectious Diseases at Boston Medical Center, and Boston Healthcare for the Homeless Program.

References

[1] Brown TT, Qaishe RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS Lond Engl 2006;20:2165–74.

[2] Buttalora L, Bucharz K, Armon C, et al. Low bone mineral density and risk of incident fracture in HIV-infected adults. Antivir Ther 2016;21:45–54.

[3] Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012;26:285–93.

[4] Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2010;5:e117217.

[5] Sharma A, Shqipo B, Hoover DR, et al. Increased fracture incidence in middle-aged HIV-infected and HIV-uninfected women: updated results From the women's interagency HIV study. J Acquir Immune Defic Syndr 2015;70:54–61.

[6] Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk among men with or at risk for HIV infection. AIDS Lond Engl 2007;21:617–23.

[7] Young B, Dao CN, Buchak K, et al. The HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis 2011;52:1061–8.

[8] Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499–504.

[9] Brown TT, Mallon PW. Editorial: working towards an understanding of bone disease in HIV. Curr Opin HIV AIDS 2016;11:251–2.

[10] Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012;205(suppl 3):S391–8.

[11] Cotter AG, Sabin CA, Simelane S, et al. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 2014;28:2051–60.

[12] Hileman CO, Labbate DE, Storer NJ, et al. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS Lond Engl 2014;28:1739–67.

[13] Gutiérrez F, Massi M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2010;13:109–18.

[14] Cotter EJ, Malizia AP, Chew N, et al. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007;23:1521–30.

[15] Fakrudin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor (B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. J Biol Chem 2003;278:48251–8.

[16] Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554–61.

[17] Escota GV, Mondy K, Bush T, et al. High prevalence of low bone mineral density and substantial bone loss over 4 years among HIV-infected persons in the era of modern antiretroviral therapy. AIDS Res Hum Retroviruses 2015;32:59–67.

[18] Hansen A, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011;12:157–65.

[19] Grijzen ML, Vrouwenraets SM, Steingroover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010;24:2233–8.

[20] Beuera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917–23.

[21] Brown TT, Moser C, Currier JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 2015;212:1241–9.

[22] Tebas P, Powerly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS Lond Engl 2000;14:F63.

[23] McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937–46.

[24] Yin MT, Lu D, Cremers S, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010;53:202–8.

[25] Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS 2010;5:126–32.

[26] Morán CA, Weitzmann MN, Oftotokun I. The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 2016;11:333–42.

[27] Oftotokun I, Titiani K, Vunnava A, et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 2016;30:405–14.

[28] Oftotokun I, Titiani K, Vukulina T, et al. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 2015;6:6282.

[29] Mondy K, Yarasheski K, Powerly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003;36:482–90.

[30] Casado JL, Bañon S, Andrés R, et al. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int 2014;25:1071–9.

[31] Hileman CO, Overton ET, McComsey GA. Vitamin D and bone loss in HIV. Curr Opin HIV AIDS 2016;11:277–84.

[32] Yin M, Vitamin D, bone, and HIV infection. Top Antivir Med 2011;19:106–18.

[33] Mansky A, Aging, human immunodeficiency virus, and bone health. Clin Interv Aging 2010;5:285–92.

[34] Kim TW, Alford DP, Malabanan A, et al. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006;85:258–62.

[35] Sharma A, Flom PL, Weiden J, et al. Antiretroviral therapy induces a substantial increase in bone mineral density and reduces bone turnover in human immunodeficiency virus-infected persons. J Acquir Immune Defic Syndr 2006;45:134–40.

[36] Coopler OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003;37(suppl 2):S232–6.

[37] Samet JH, Cheng DM, Libman H, et al. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007;46:194–9.

[38] Justice AC, McGinnis KA, Tate JP, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV.
infected compared with uninfected men. Drug Alcohol Depend 2016;161:95–101.
[39] Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001;16:83–8.
[40] Galvan IH, Bing EG, Fleshman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002;63:179–86.
[41] Howe CJ, Cole SR, Ostraw DG, et al. A prospective study of alcohol consumption and HIV acquisition among injection drug users. AIDS Lond Engl 2011;25:221–8.
[42] Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients. Drugs 2006;66:769–89.
[43] Chakalalakal DA. Alcohol-induced bone loss and deficient bone repair. Alcohol Clin Exp Res 2005;29:2077–90.
[44] Shimizu Y, Sakai A, Menuki K, et al. Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2–deficient mice. Bone 2011;48:1075–86.
[45] Rico H, Cabranes J, Cabello J, et al. Low serum osteocalcin in acute alcohol intoxication: a direct toxic effect of alcohol on osteoblasts. Bone Miner 1987;2:221–5.
[46] Frady KE, Howard GA, Ethanol inhibits human bone cell proliferation and function in vitro. Metabolism 1991;40:562–5.
[47] Giuliani N, Girasole G, Vescovi P, et al. Ethanol and acetaldehyde inhibit the formation of early osteoblast progenitors in murine and human bone marrow cultures. Alcohol Clin Exp Res 1999;23:381–5.
[48] González-Reimers E. Bone changes in alcoholic liver disease. World J Gastroenterol 2005;11:1661–5.
[49] Skinner HA. Lifetime Drinking History: Administration and Scoring Guidelines. Addiction Research Foundation, Toronto, Canada:2004.
[50] Hatton J, Burton A, Nash H, et al. Drinking patterns, dependency and life-time drinking history in alcohol-related liver disease. Addict Abingdon Engl 2009;104:587–92.
[51] Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001;16:83–8.
[52] Sebring NG, Denkinger BI, Menzies CM, et al. Validation of three food frequency questionnaires to assess dietary calcium intake in adults. J Am Diet Assoc 2007;107:752–9.
[53] McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980;168:26–33.
[54] Farrell C-JL, Martin S, McWhinney B, et al. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem 2012;58:531–42.
[55] Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS Lond Engl 2010;24:2827–33.
[56] Cazanave C, Dupon M, Lavigolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS Lond Engl 2008;22:395–402.
[57] Tiani K, Vunvava A, Sherb AN, et al. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog 2014;10:e1004497.
[58] Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV-infected adults. AIDS Lond Engl 2009;23:1021–4.
[59] Kooij KW, Wit FWNM, Bisschop PH, et al. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis 2015;211:539–48.
[60] Gill US, Zissimopoulos A, Al-Shamma S, et al. Assessment of bone mineral density in tenovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis 2015;211:374–82.
[61] Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or Placebo in Botswana. PLoS One 2014;9:e90111.
[62] Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009;23:1519–29.
[63] Mukamal KJ, Robbins JA, Caulry JA, et al. Alcohol consumption, bone density, and hip fracture among older adults: the cardiovascular health study. Osteoporos Int 2007;18:593–602.
[64] Alvisa-Negrin J, Gonzalez-Reimers E, Santolaria-Fernandez F, et al. Osteopenia in alcoholics: effect of alcohol abstinence. Alcohol Alcohol 2009;44:468–75.
[65] Steffelbrink H, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963–72.
[66] Gallant JE, Staszewski S, Pozniak AL, et al. Efficiency virus-infected women. J Clin Endocrinol Metab 2006;91:2938–45.
[67] McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980;168:26–33.
[68] Littin RZ. Timeline follow-back. Measuring Alcohol Consumption 1992; Springer, 41–72.
[69] Dolan SE, Kantor JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006;91:2938–45.
[70] Lorkiewicz S. Marijuana use, heavy drinking, and cognitive dysfunction in people with human immunodeficiency virus infection [Internet]. 2015. Available from: http://search.proquest.com/docview/1657861433?accountid=9676. Accessed December 16, 2015.
[71] Fan B, Lu Y, Genant H, et al. Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporos Int 2010;21:1227–36.